A. Menarini Pharma GmbH ist eine österreichische Tochtergesellschaft der Menarini Group/Florenz.
Lesen Sie die neuesten Nachrichten von der Menarini Gruppe.
A. Menarini Pharma GmbH is an Austrian subsidiary of the Menarini Group/Florence.
Read the latest news from the Menarini Group.
Quofenix® is a broad-spectrum fluoroquinolone antibiotic.1
Quofenix® (delafloxacin) is an antibiotic from the fluoroquinolone group that is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI*) and community-acquired pneumonia (CAP**) in adults as monotherapy. In addition to its very broad spectrum of activity, both in the gram-negative and the gram-positive spectrum (incl. MRSA)1, the unique anionic structure of delafloxacin gives it increased intracellular penetration and enhanced bactericidal activity under acidic conditions that characterize the environment at a number of infection sites.2,3
With respect to known side effects from the class of fluoroquinolones, Quofenix® has a favorable tolerability profile because, unlike other fluoroquinolones, it shows no evidence of QT time prolongation or phototoxicity.4 Quofenix® is available as both an i.v. formulation and a tablet, allowing for optimal patient management.
* ABSSSI = acute bacterial skin and skin structure infections, ** CAP = community-acquired pneumonia
References: 1 Drug information, 2 Jorgensen SCJ, et al. lnfect Dis Ther. 2018;7(2):197-217, 3 Lemaire S, et al. Antimicrob Agents Chemother. 2011;55(2):649-658, 4 Lodise T. et al., Open Forum lnfect Dis 2018; 5(10)
AT-WEB-17-10-2021